Evidence map›Paper›PMID 41926452›Full record

ArticlePLoS biology2026

Specificity and recognition of the ADP-ribosyl-ubiquitin modification in the DNA damage response.

Chatrin Chatrin, Kang Zhu, Michael D R Simmons, Lucy Maginn, Kira Schützenhofer, Yang Lu, Nina Đukić, Sven Wijngaarden, Max S Kloet, Katarzyna Wiktoria Kliza and 5 more

Abstract read
In one paragraph

Article in PLoS biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Chatrin ChatrinSir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
Kang ZhuSir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
Michael D R SimmonsSir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
Lucy MaginnSir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
Kira SchützenhoferSir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
Yang LuSir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
Nina ĐukićSir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
Sven WijngaardenLeiden Institute of Chemistry, Leiden University, Leiden, The Netherlands.
Max S KloetDepartment of Cell and Chemical Biology, Leiden University Medical Centre, Leiden, The Netherlands.
Katarzyna Wiktoria KlizaMax Planck Institute of Molecular Physiology, Dortmund, Germany.
Gerbrand J van der Heden van NoortDepartment of Cell and Chemical Biology, Leiden University Medical Centre, Leiden, The Netherlands.
Dmitri V FilippovLeiden Institute of Chemistry, Leiden University, Leiden, The Netherlands.
Dragana AhelSir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
Rebecca SmithSir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
Ivan AhelSir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.ORCID https://orcid.org/0000-0002-9446-3756

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ADP-ribosylation (ADPr) is a post-translational modification that has regulatory roles in multiple cellular pathways including the DNA damage response and in innate immunity. Recently, it has been uncovered that ADP-ribose can be further modified by a family of ubiquitin E3 ligases, the DELTEXES, which catalyze ubiquitin transfer directly onto ADP-ribose, creating a hybrid ADPr-Ub modification which can be recognized by proteins with dedicated ADPr-Ub binding domains. With this hybrid modification recently been identified in cellular systems, we use a series of in vitro and cellular assays in human cells to investigate the amino acid preference for ADPr-Ub production as well as conditions required for reversal of the modification. We show that ADPr on both serine and glutamate-linked peptides can be ubiquitinated by the RING-DTC domains of DTX2 and DTX3L in vitro and that this can be recognized by RNF114, RNF138 and RNF166 for ubiquitin chain elongation. Finally, we demonstrate that DTX2 rather than DTX3L plays a role in ADPr-Ub production at sites of DNA damage to promote the recruitment of RNF114, RNF138, and RNF166 in an HPF1-independent manner.

Indexed as

Adenosine Diphosphate RiboseADP-RibosylationDNA DamageUbiquitinCarrier ProteinsHEK293 CellsHumansNuclear ProteinsProtein Processing, Post-TranslationalUbiquitinationUbiquitin-Protein LigasesAdenosine Diphosphate RiboseCarrier ProteinsHPF1 protein, humanNuclear ProteinsUbiquitinUbiquitin-Protein Ligases

Identifiers

PMID41926452
PMCPMC13061329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.